N-(2,4-difluorobenzyl)-4-(2-{[2-methoxy-4-(methylsulfonyl)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)benzamide | 1403331-13-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2,4-difluorobenzyl)-4-(2-{[2-methoxy-4-(methylsulfonyl)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)benzamide
• 英文别名: N-[(2,4-difluorophenyl)methyl]-4-[2-(2-methoxy-4-methylsulfonylanilino)-[1,2,4]triazolo[1,5-a]pyridin-6-yl]benzamide
• CAS: 1403331-13-4
• 化学式: C₂₈H₂₃F₂N₅O₄S
• 分子量: 563.585
• InChiKey: HJEMLGQBMCZWPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  40
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  123
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  2-溴-5-氟苯甲醚 在 bis-triphenylphosphine-palladium(II) chloride 、 potassium phosphate 、 chloro(2-dicyclohexylphosphino-2′,4′,6′-tri-isopropyl-1,1′-biphenyl)[2-(2-aminoethyl)phenyl] palladium(II) methyl-tert-butylether 、 potassium carbonate 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 间氯过氧苯甲酸 、 三苯基膦 、 2-二环己基磷-2,4,6-三异丙基联苯 、 碘甲烷 作用下， 以 丙醇 、 氯仿 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 102.5h， 生成 N-(2,4-difluorobenzyl)-4-(2-{[2-methoxy-4-(methylsulfonyl)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)benzamide
  参考文献：
  名称：

  METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES

  摘要：

  本发明涉及根据本文所描述和定义的一般式（I）制备取代三唑吡啶化合物的方法，以及用于制备所述化合物的中间体化合物。

  公开号：

  US20150148542A1

文献信息

• [EN] METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES<br/>[FR] PROCÉDÉ DE PRÉPARATION DE TRIAZOLOPYRIDINES SUBSTITUÉES
  申请人：BAYER PHARMA AG

  公开号：WO2014009219A1

  公开（公告）日：2014-01-16

  The present invention relates to methods of preparing substituted triazolopyridine compounds of general formula (I) as described and defined herein, as well as to intermediate compounds useful in the preparation of said compounds.

  本发明涉及制备通式（I）所述和定义的取代三唑吡啶化合物的方法，以及用于制备所述化合物的中间体化合物。
• [EN] TRIAZOLOPYRIDINES<br/>[FR] TRIAZOLOPYRIDINES
  申请人：BAYER IP GMBH

  公开号：WO2012143329A1

  公开（公告）日：2012-10-26

  The present invention relates to triazolopyridine compounds of general formula (I) : in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.

  本发明涉及一般式（I）的三唑吡啶化合物，其中R1、R2、R3、R4和R5如描述和权利要求中所述，涉及制备该化合物的方法，包括该化合物的药物组合物和组合物，用于制造治疗或预防疾病的药物组合物的用途，以及用于制备该化合物的中间化合物。
• TRIAZOLOPYRIDINES
  申请人：Schulze Volker

  公开号：US20140120087A1

  公开（公告）日：2014-05-01

  The present invention relates to triazolopyridine compounds of general formula (I): in which R 1 , R 2 , R 3 , R 4 , and R 5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.

  本发明涉及通式（I）的三唑吡啶化合物，其中R1、R2、R3、R4和R5如描述和权利要求中所给出，以制备所述化合物的方法，包括包含所述化合物的药物组合物和组合物，以及用于制造用于治疗或预防疾病的药物组合物的所述化合物的用途，以及用于制备所述化合物的中间体化合物。
• US9388177B2
  申请人：——

  公开号：US9388177B2

  公开（公告）日：2016-07-12
• [EN] COMBINATIONS FOR THE TREATMENT OF CANCER<br/>[FR] COMBINAISONS POUR LE TRAITEMENT DU CANCER
  申请人：BAYER PHARMA AG

  公开号：WO2014020043A1

  公开（公告）日：2014-02-06

  The present invention relates to combinations of at least two compounds A and B, compound A being an inhibitor of Mps-1 kinase, and compound B being an inhibitor of an anti-apoptotic protein of the Bcl-2 family. Another aspect of the present invention relates to the use of such combinations as described supra for the preparation of a medicament for the treatment or prophylaxis of a disease, particurlarly for the treatment of cancer. Another aspect of the present invention relates to the use of an anti-apoptotic protein from the Bcl-2 family as a sensitizer of cells to Mps-1 inhibitors. Another aspect of the present invention relates to the use of the ratio of pro-apoptotic and anti-apoptotic proteins from the Bcl-2 family in a biological sample as a biomarker for a Mps-1 kinase inhibitor treatment.